UNSPSC 51314375: Pheniramine/phenylpropanolamine/phenyltoloxamine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314375 Pheniramine/phenylpropanolamine/phenyltoloxamine/pyrilamine is a Commodity code that in practice spans a broader range of pharmaceutical and over-the-counter products than its specific name suggests. State and local governments procure generic pharmaceuticals, naloxone, drug deactivation systems, and OTC products under this code through competitive bidding and cooperative purchasing mechanisms. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The Seminole County, Florida procurement for naloxone and drug deactivation systems exemplifies direct county-level purchasing for community health initiatives, while the Texas Health and Human Services Commission's Request for Information on Direct-to-Manufacturer Prescriptions and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic pharmaceuticals and OTC products reflect state-level and cooperative purchasing approaches that serve multiple jurisdictions. Vendors typically must maintain cGMP and Drug Supply Chain Security Act compliance, carry substantial insurance coverage including commercial general liability, and meet E-Verify and drug-free workplace requirements.

Recent activity clusters in Florida, Texas, and the upper Midwest, with the Minnesota cooperative serving participating states including Oregon. The Seminole County IFB (IFB60459723LAS) posted June 30, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023, response deadline. The Texas HHS RFI (HHS0017013) posted April 3, 2026, explored vendor capabilities for direct-to-manufacturer prescription programs without a formal award value. The Minnesota MMCAP RFP (S1070000015802) posted January 20, 2026, established multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with proposals due March 26, 2026, and awards effective July 1, 2026; evaluation weighted price competitiveness at 75 percent and required vendors to agree to a 3 percent administrative fee. Vendors bidding under this code should expect performance penalties for late reporting or missed onboarding timelines and must demonstrate pricing flexibility across multiple net-price and WAC-minus formats.